Glioma-Targeting Aptamer Conjugates for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in specifically delivering diagnostic and therapeutic agents to tumor tissues, particularly glioma cells, with a need for improved targeting and delivery efficiency.
Innovation Solution
Development of an aptamer with a specific nucleotide sequence that can be covalently conjugated with functional groups to form a conjugate, enabling targeted delivery of diagnostic and therapeutic agents to tumor cells, especially glioma cells, and overcoming the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional delivery methods are used to deliver diagnostic and therapeutic agents to tumor tissues, then the delivery process can be implemented, but the targeting specificity and delivery efficiency to tumor cells, especially glioma cells, are insufficient
Solution Approach 1:
The patent applies parameter changes by designing an aptamer with a specific nucleotide sequence (Formula 1) that has been optimized to recognize and bind to tumor cells, especially glioma cells. The aptamer sequence parameters (length, composition, secondary structure) are carefully controlled to achieve high targeting specificity while maintaining efficient cellular uptake and delivery of therapeutic agents.
Solution Approach 2:
The aptamer serves as an intermediary molecule that mediates between the delivery system and tumor cells. It acts as a bridge that specifically binds to tumor cell surfaces and facilitates the delivery of diagnostic and therapeutic agents into tumor cells, thereby improving both targeting specificity and delivery efficiency simultaneously.
2Reliability
If aptamers are designed and synthesized to target tumor cells, then targeting capability can be achieved, but the complexity of designing and optimizing the aptamer sequence increases
Solution Approach 1:
The aptamer is segmented into distinct functional regions as described in Formula (1): T1 and T2 regions, S1 and S4 motifs, Na and Nc segments, and S2 and S3 motifs. This segmentation allows for systematic design and optimization of each region's contribution to targeting capability, reducing the overall design complexity while maintaining high reliability.
Solution Approach 2:
The aptamer design incorporates universal principles that can be applied across different tumor types. The modular structure with conserved motifs (S1-S4, Na-Nc) provides a framework that can be adapted for various tumor cell types, reducing the need to redesign from scratch and thereby reducing complexity while maintaining reliable targeting capability.
3Measurement precision
If the aptamer sequence is optimized for high specificity to tumor cells, then targeting accuracy improves, but the synthesis and production cost increases
Solution Approach 1:
The patent optimizes the aptamer sequence parameters within practical synthesis constraints. The length (20-50 nucleotides) and composition (with specific proportions of A, U, C, G) are controlled to achieve high targeting accuracy while remaining compatible with standard chemical synthesis methods, thereby balancing manufacturing ease with targeting precision.
Solution Approach 2:
The aptamer is designed as a synthetic oligonucleotide that can be produced through established chemical synthesis methods. The design avoids the need for complex biological production systems or rare modifications, allowing for cost-effective synthesis while maintaining high targeting accuracy through careful sequence selection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamer-conjugate system effectively targets and delivers diagnostic and therapeutic agents to tumor cells, enhancing diagnostic accuracy and therapeutic efficacy, including significant tumor inhibition and reduced side effects.
Implementation Method 1
Aptamers, also known as nucleic acid aptamers, are oligonucleotide molecules that can bind to various molecules of interest, such as small molecule compounds, proteins, nucleic acids, and even cells, tissues and organs. The aptamers can provide the important property of 'recognizing specific molecules'
Implementation Method 2
each of the delivery groups is independently linked to the functional group via a covalent bond or via a linking group
Data Source
AI summary
Provided is an aptamer, comprising a continuous nucleotide sequence having a sequence set forth in formula (1). Also provided is a conjugate comprising: a delivery group formed by the aptamer, and a functional group. The aptamer provided herein can specifically target and internalize into a tumor cell. The conjugate provided can deliver the functional group to a tumor tissue in a targeted manner, so as to diagnose and/or treat tumors and tumor-related diseases.